Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2012 2
2016 1
2017 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis an …
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density …
HER2 testing in gastric cancer: results of a German expert meeting.
Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. Lordick F, et al. J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11. J Cancer Res Clin Oncol. 2017. PMID: 28285403 Free PMC article. Review.
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.
Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfeld C, Schirmacher P, Penzel R, Endris V, Stenzinger A. Kirchner M, et al. Cancers (Basel). 2019 Sep 5;11(9):1309. doi: 10.3390/cancers11091309. Cancers (Basel). 2019. PMID: 31491926 Free PMC article.
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL). Schmitz N, et al. Lancet Oncol. 2012 Dec;13(12):1250-9. doi: 10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16. Lancet Oncol. 2012. PMID: 23168367 Clinical Trial.
BACKGROUND: High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-line therapy in young patients with high-risk aggressive B-cell lymphoma. We investigated whether HDT with cytotoxic agents identical t …
BACKGROUND: High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-li …
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; German CLL Study Group. Dreger P, et al. Blood. 2012 May 24;119(21):4851-9. doi: 10.1182/blood-2011-09-378505. Epub 2012 Apr 5. Blood. 2012. PMID: 22490331 Free article. Clinical Trial.
Studies of the producer cell of interferon in human lymphocyte cultures.
Kirchner H, Peter HH, Hirt HM, Zawatzky R, Dalügge H, Bradstreet P. Kirchner H, et al. Immunobiology. 1979 Aug;156(1-2):65-75. Immunobiology. 1979. PMID: 94306
Thus, our data indicate that interferon is produced by non-T, non-B cells, possibly by cells related to NK cells....
Thus, our data indicate that interferon is produced by non-T, non-B cells, possibly by cells related to NK cells....
Proceedings of the 3rd Biennial Conference of the Society for Implementation Research Collaboration (SIRC) 2015: advancing efficient methodologies through community partnerships and team science : Seattle, WA, USA. 24-26 September 2015.
Lewis C, Darnell D, Kerns S, Monroe-DeVita M, Landes SJ, Lyon AR, Stanick C, Dorsey S, Locke J, Marriott B, Puspitasari A, Dorsey C, Hendricks K, Pierson A, Fizur P, Comtois KA, Palinkas LA, Chamberlain P, Aarons GA, Green AE, Ehrhart MG, Trott EM, Willging CE, Fernandez ME, Woolf NH, Liang SL, Heredia NI, Kegler M, Risendal B, Dwyer A, Young V, Campbell D, Carvalho M, Kellar-Guenther Y, Damschroder LJ, Lowery JC, Ono SS, Carlson KF, Cottrell EK, O’Neil ME, Lovejoy TL, Arch JJ, Mitchell JL, Lewis CC, Marriott BR, Scott K, Coldiron JS, Bruns EJ, Hook AN, Graham BC, Jordan K, Hanson RF, Moreland A, Saunders BE, Resnick HS, Stirman SW, Gutner CA, Gamarra J, Vogt D, Suvak M, Wachen JS, Dondanville K, Yarvis JS, Mintz J, Peterson AL, Borah EV, Litz BT, Molino A, McCaughan SY, Resick PA, Pandhi N, Jacobson N, Serrano N, Hernandez A, Schreiter EZ, Wietfeldt N, Karp Z, Pullmann MD, Lucenko B, Pavelle B, Uomoto JA, Negrete A, Cevasco M, Kerns SEU, Franks RP, Bory C, Miech EJ, Damush TM, Satterfield J, Satre D, Wamsley M, Yuan P, O’Sullivan P, Best H, Velasquez S, Barnett M, Brookman-Frazee L, Regan J, Stadnick N, Hamilton A, Lau A, Regan J, Hamilton A, Stadnick N, Barnett M, Lau A, Brookma… See abstract for full author list ➔ Lewis C, et al. Implement Sci. 2016 Jun 23;11 Suppl 1(Suppl 1):85. doi: 10.1186/s13012-016-0428-0. Implement Sci. 2016. PMID: 27357964 Free PMC article.
Chinman, Laura Damschroder, Jeffrey L. Smith, Monica M. Matthieu, Enola K. Proctor, JoAnn E. Kirchner A23: Structuring complex recommendations: Methods and general findings Thomas J. ...Chinman, Laura J. Damschroder, Jeffrey L. Smith, Enola K. Proctor, JoAnn E. Kirchner …
Chinman, Laura Damschroder, Jeffrey L. Smith, Monica M. Matthieu, Enola K. Proctor, JoAnn E. Kirchner A23: Structuring complex recomm …